AbCellera Q3 revenue plunges to $6.6M from $101M; net loss $0.10/sh vs prior year profit

AbCellera Biologics Inc.

2023-Q3 EPS reported -$0.34 revenue$28,846,000

Total revenue $6.6M, down 93.5% from $101.4M in Q3 2022.
Net loss of $28.6M ($0.10 loss per share) vs net earnings of $26.6M ($0.09 EPS) in Q3 2022.
Cumulative partnered program starts reached 110, up 20% YoY; 10 molecules in clinic.
Two AbCellera-led programs advanced into IND-enabling studies.
Cash, cash equivalents, and marketable securities $813.0M; R&D expenses $37.9M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AbCellera Biologics Inc. reported the quarter ended September 30, 2023 results: revenue $6.6 million, net income net loss of $28.6 million, EPS $(0.10) per share on a basic and diluted basis.

Period: the quarter ended September 30, 2023
Revenue: $6.6 million
Net income: net loss of $28.6 million
EPS: $(0.10) per share on a basic and diluted basis
Result: reported results

Exact text from the filing

value, both through strategic partnerships, and through internal discovery and development of potential first-in-class antibody therapies.” Q3 2023 Business Summary ● Earned $6.6 million in total revenue. ● Generated a net loss of $28.6 million, compared to net earnings of $26.6 million in Q3 2022. ● Reached a cumulative total of 182 programs under contract with

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

AbCellera Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001703057-23-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.